CTLA4 and hepatocellular carcinoma: Other immune-checkpoint blockades including anti-PD-L1 antibody (durvalumab) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody (tremelimumab) were under clinical investigation as a combined therapy and revealed to improve the progression-free survival of patients with unresectable HCC [183].